Lessons
from immune response (immunity) of most severe Covid patients
New research has found that
even the most ill Covid-19 patients produce T cells that help fight the virus.
T cells are an integral part of your immune system (immunity) and their roles include
killing infected cells, using other immune cells, and
regulating the immune response system (immunity). This study demonstrates the findings as
existing evidence that the Covid-19 vaccine (whenever it is established) will
need to release T cells to work together with antibodies. The new study was
published in the journal Science Immunology on Friday.
Investigators followed 10
critically ill Covid-19 patients at Erasmus University Medical Center, in the
Netherlands. Two patients eventually died. A closer look at their immune
responses (immunity) shows that all 10 patients produced T cells that were specific to the
SARS-CoV-2 virus. These T cells have worked with antibodies to try to clear the
virus and prevent infection. Investigators note that these findings are the
latest inline study, published in Cell, which showed a strong cell response in
people with moderate Covid-19 conditions. In both studies, T cells in these
patients clearly identified the “spike” protein in SARS-CoV-2.
Spike protein used by
coronavirus to enter human cells. This new study adds to the growing evidence
that spike protein is a promising target. It ensures that the immune system (immunity) can show strong responses to other viruses.
"This is good news for those who develop a vaccine using a boat, and we
also propose new ways to increase the likelihood of vaccination," said
researcher in new study. While the Cell paper
followed the citizens of San Diego, a new paper followed the Dutch patients —
and the T cell responses were consistent across both populations. "This
study is important because it shows the immune response of patients from many
kilometers. Similar observations are now being reproduced in different
countries and disciplines.
MMR
vaccine can help fight sepsis in Covid patients: study
A new paper suggests that live
riding vaccines such as MMR (measles, mumps and rubella) can prevent acute lung
inflammation and sepsis associated with Covid-19 infection. This paper is
published online in mBio magazine. Alive attenuated vaccine is available from
an infectious disease virus, which has been weakened in the laboratory so that
it does not cause severe infections when vaccinated.
A new research paper refers to
the growing evidence that live vaccines can activate specific immune cells to
train leukocytes (white blood cells) to incorporate more effective protection
against unrelated diseases. Researchers have used an existing vaccine
formulation and showed, in this lab, that vaccines trained on the internal
protection against sepsis (blood poisoning) caused by a combination of fungal
and bacterial infections. The authors propose that the defense is composed of
cells called MDSCs. They emphasized that this proposed MMR vaccine concept was
not suggested to be directed against Covid19, but instead the immune system in
the acute inflammatory markers of Covid-19.
This study was done by Paul
Fidel Jr of LSU Health New Orleans, and the Mairi Noverr of Tulane University
School of Medicine in New Orleans. Dr Fidel said in a statement: "The use
of childhood vaccines such as MMR given to adults to use stander cells may
reduce the serious complications associated with low-risk Covd-19 virus is - a
major preventative benefit during the epidemic. These are long-lived stander
cells but Any person who has been vaccinated against childhood MMR, while they
may still have measles, mumps, or rubella immune cells, will not have
sepsis-directed immune cells. you are better protected from Covid-related
sepsis. "
Study
projects 95 thousands additional TB deaths in India due to Covid
New measurement studies have
estimated that the Covid-19 epidemic could significantly increase the global
burden of tuberculosis due to interruptions in health services, and delays in
diagnosis and treatment. In India, it estimates that TB will cause 95,000 more
deaths in the next five years. The study is published in the European
Respiratory Journal. Investigators estimate additional TB deaths and cases in
China, India and South Africa over the next five years.
They pointed out that public
distribution could reduce the incidence of TB as the viruses behind the disease
are transmitted by the drops - the same Tothe coronavirus. Even after taking
these targeted reductions, the probable cause scenario resulted in more than
110,000 TB deaths (95,000 in India, 13,000 in South Africa and 6,000 in China).
In a worst-case scenario, this number could increase to 200,000 deaths,
researchers estimate. Researchers have cited preliminary data from China, India
and South Africa which shows that the number of people diagnosed with TB has
dropped dramatically.
These three countries make up
approximately 40% of the global TB cases. Researchers have measured various
scenarios with the use of several measures of community distribution and a
six-month health service interruption, to come up with their own estimates.
This study was conducted by researchers from the London School of Hygiene &
Tropical Medicine and Lancaster University.